Venclexta has also been granted five Breakthrough Therapy Designations by the FDA, including two for previously untreated AML. Venclexta/Venclyxto is being developed by AbbVie and Roche.

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.Top-line results from the CLL14 ...

Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta ...

Roche RHHBY announced that the FDA has granted full approval to leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).. The combination has been approved ...

For Venclexta, it’s the first FDA nod outside of the chronic lymphocytic leukemia arena, where it won its first OK back in 2016. Since then, AbbVie and Roche have successfully expanded the drug ...

RELATED: AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena In November 2018, the FDA approved Venclexta as a combination therapy with any of three chemo options to treat ...

Venclexta, a BCL-2 inhibitor that AbbVie markets with Roche’s Genentech division, was approved in 2016 for second-line chronic lymphocytic leukemia, or CLL, that harbors a mutation known as ...

The FINANCIAL — Roche announced on April 12 that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta (venetoclax) for the treatment of people with chronic ...

(RTTNews) - Roche (RHHBY) announced the FDA has granted full approval of Venclexta (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly ...

Roche's another AML drug, idasanutlin, is researched with cytarabine (phase 3) for R/R AML, with Venclexta for treatment of R/R AML in patients unfit for chemo (Phase 2), and also with cytarabine ...

Roche Holdings AGRHHBY announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed ...